Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study

INTRODUCTION: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer's disease (AD). AMYPAD PNHS adds (semi‐)quantitative amyloid PET imaging to several Eu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes Alves, Isadora, Collij, Lyduine E., Altomare, Daniele, Frisoni, Giovanni B., Saint‐Aubert, Laure, Payoux, Pierre, Kivipelto, Miia, Jessen, Frank, Drzezga, Alexander, Leeuwis, Annebet, Wink, Alle Meije, Visser, Pieter Jelle, van Berckel, Bart N.M., Scheltens, Philip, Gray, Katherine R., Wolz, Robin, Stephens, Andrew, Gismondi, Rossella, Buckely, Christopher, Gispert, Juan Domingo, Schmidt, Mark, Ford, Lisa, Ritchie, Craig, Farrar, Gill, Barkhof, Frederik, Molinuevo, José Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Featured Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984341/
https://www.ncbi.nlm.nih.gov/pubmed/32281303
http://dx.doi.org/10.1002/alz.12069
Descripción
Sumario:INTRODUCTION: The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) Prognostic and Natural History Study (PNHS) aims at understanding the role of amyloid imaging in the earliest stages of Alzheimer's disease (AD). AMYPAD PNHS adds (semi‐)quantitative amyloid PET imaging to several European parent cohorts (PCs) to predict AD‐related progression as well as address methodological challenges in amyloid PET. METHODS: AMYPAD PNHS is an open‐label, prospective, multi‐center, cohort study recruiting from multiple PCs. Around 2000 participants will undergo baseline amyloid positron emission tomography (PET), half of whom will be invited for a follow‐up PET 12 at least 12 months later. RESULTS: Primary include several amyloid PET measurements (Centiloid, SUVr, BP(ND), R(1)), and secondary are their changes from baseline, relationship to other amyloid markers (cerebrospinal fluid and visual assessment), and predictive value of AD‐related decline. EXPECTED IMPACT: Determining the role of amyloid PET for the understanding of this complex disease and potentially improving secondary prevention trials.

Ejemplares similares